Skip to content
Lower risk Drug recall · FDA · Published September 17, 2018

Endo Robaxin 750mg Tablets: Incorrect Dosage Label Recall

Endo Pharmaceuticals recalls Robaxin 750mg tablets due to incorrect dosage instructions on labels. This could lead to unsafe dosing if users follow the wrong label instructions.

🇺🇸 FDA recall #D-0009-2019DrugEndo Pharmaceuticals ›
Take action

Contact the company

Recalling firmEndo Pharmaceuticals, Inc.1400 Atwater Dr · Malvern, PA 19355-8701
✎ GovInfoNow plain-language explainer

Endo Pharmaceuticals is recalling Robaxin 750mg tablets because the label incorrectly states "two to four tablets four times daily" instead of "two tablets three times daily." This could lead to taking too many pills and potential overdose risk. Read more at govinfonow.com/recall/39564-endo-robaxin-750mg-tablets-incorrect-dosage-label-recall.

Source Summary by GovInfoNow · govinfonow.com/recall/39564-endo-robaxin-750mg-tablets-incorrect-dosage-label-recall · Updated October 6, 2026 · FDA enforcement record: FDA #D-0009-2019

Cite this page

“Endo Robaxin 750mg Tablets: Incorrect Dosage Label Recall.” GovInfoNow, updated October 6, 2026. https://govinfonow.com/recall/39564-endo-robaxin-750mg-tablets-incorrect-dosage-label-recall. Based on FDA recall #D-0009-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0009-2019%22&limit=1).

Endo Pharmaceuticals, Inc. recalled robaxin-750 (methocarbamol tablets, USP), 750 mg, 100-count bottles due to incorrect dosage instructions on the label, according to the FDA. The Food and Drug Administration announced the Class I recall on September 17, 2018.

How to tell if you have it

  • Brand: Endo Pharmaceuticals
  • Product: robaxin-750 (methocarbamol tablets, USP), 750 mg, 100-count bottle
  • NDC: 52244-449-10
  • Lot codes: 216702P1 (Exp 09/20) and 220409P1 (Exp 01/21)
  • Quantity: 2,856 bottles

The hazard

The immediate container label incorrectly states the dosage as "Two to four tablets four times daily" instead of the correct "Two tablets three times daily." The FDA classified this labeling error as a Class I recall.

Context

GovInfoNow's records show Endo Pharmaceuticals, Inc. has had four other recalls since May 7, 2012. Other recent recalls of similar products include Greenstone Methylprednisolone Tablets Recall (January 15, 2026), Alvogen Thyro-Tabs 150mcg Tablets Recall (December 31, 2025), and American Regent Levocarnitine Injection Recall (April 16, 2026).

How to tell if you have this one

Check for Robaxin 750mg tablets with lot numbers 216702P1 (expiring September 2020) or 220409P1 (expiring January 2021). The product is only available by prescription.

  • Brand
    Endo Pharmaceuticals
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Label Instructions

    Review the dosage instructions on the label to ensure they match the correct dosage of two tablets three times daily.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA.” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 17 months after the firm started it.

1. Firm started the recall: Sep 17, 201812. FDA classified it Class I: Oct 9, 201823. Published in FDA’s Enforcement Report: Oct 10, 201834. FDA terminated the recall: Feb 4, 2020420182020
  1. Firm started the recall
  2. FDA classified it Class I
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0009-2019 (September 17, 2018) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0009-2019 to see it in context.
  • Plain-language summary written by qwen3:4b on October 6, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA